NCT06890338 - A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2029

Conditions

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal CancerNeoadjuvant

Interventions

DRUG

Carboplatin

Intravenous (IV) infusion

DRUG

Mirvetuximab Soravtansine

Intravenous (IV) infusion

DRUG

Bevacizumab

Intravenous (IV) infusion (per investigator's discretion)

Trial Locations (9)

West Virginia University School of Medicine /ID# 274556, Morgantown

Mount Sinai Medical Center /ID# 274868, Miami

Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 274780, Saint Louis Park

Cox Medical Center South /ID# 274826, Springfield

Trials 365 /ID# 274310, Shreveport

The Center Of Hope /ID# 274313, Reno

Danbury Hospital, Western Connecticut Health Network /ID# 274783, Danbury

Norwalk Hospital /ID# 274561, Norwalk

OSF St. Francis Medical Center /ID# 274752, Peoria